Immunovant Inc’s recent filing unveils that its Chief Technology Officer Stout Jay S unloaded Company’s shares for reported $31914.0 on Jan 07 ’26. In the deal valued at $26.53 per share,1,203 shares were sold. As a result of this transaction, Stout Jay S now holds 199,611 shares worth roughly $5.2 million.
Then, Van Tuyl Christopher sold 10,813 shares, generating $290,943 in total proceeds. Upon selling the shares at $26.91, the Chief Legal Officer now owns 149,930 shares.
Before that, Roivant Sciences Ltd. bought 16,666,666 shares. Immunovant Inc shares valued at $349,999,986 were divested by the Director at a price of $21.00 per share. As a result of the transaction, Roivant Sciences Ltd. now holds 113,317,007 shares, worth roughly $2.95 billion.
Wolfe Research upgraded its Immunovant Inc [IMVT] rating to an Outperform from a a Peer perform in a research note published recently. A number of analysts have revised their coverage, including Truist’s analysts, who began to cover the stock in mid October with a ‘”a Hold”‘ rating. Jefferies started covering the stock on March 03, 2025. It rated IMVT as “a Hold”.
Price Performance Review of IMVT
On Monday, Immunovant Inc [NASDAQ:IMVT] saw its stock fall -1.06% to $26.03. Over the last five days, the stock has gained 0.46%. Immunovant Inc shares have risen nearly 5.64% since the year began. Nevertheless, the stocks have risen 2.40% over the past one year.
How much short interest is there in Immunovant Inc?
A steep rise in short interest was recorded in Immunovant Inc stocks on 2025-12-15, dropping by -1.42 million shares to a total of 14.96 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-14 was 16.38 million shares. There was a decline of -9.47%, which implies that there is a negative sentiment for the stock.
